TICKERNERD
Menu
EDVAEDVAConsumer Defensive · Beverages - Wineries & Distilleries

EDVA Stock Forecast: Endovia Health Sciences, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$0.16
+7.38% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 23 Oct 2026 — in the weakest quartile.

Market cap
$929,815.00
Ticker Nerd rank
3/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.0M
Net income−$2.1M
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.6%
1M
−22.0%
YTD
−94.2%
1Y
−98.0%
From 52W high
−98.1%
From 52W low
+18.5%
$0.14
$8.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EDVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Endovia Health Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
3/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Revisions
25
Momentum
22
Value
9
Accruals
8
Volatility
8
Quality
6
Growth
1
Issuance
0

Size (99): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EDVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EDVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26EDVA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Nov 2024HC Wainwright & Co.MaintainsBuy—
3 Sept 2024Roth MKMMaintainsBuy—
26 Aug 2024HC Wainwright & Co.ReiteratesBuy—
25 June 2024Roth MKMMaintainsBuy—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.MaintainsBuy—
20 Nov 2023EF HuttonReiteratesBuy—
14 Sept 2023EF HuttonReiteratesBuy—
16 Aug 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023EF HuttonMaintainsBuy—
27 June 2023Roth MKMInitiatesBuy—
7 June 2023HC Wainwright & Co.ReiteratesBuy—
26 Apr 2023HC Wainwright & Co.ReiteratesBuy—
5 Apr 2023HC Wainwright & Co.ReiteratesBuy—
6 Mar 2023HC Wainwright & Co.ReiteratesBuy—
14 Feb 2023HC Wainwright & Co.InitiatesBuy—
25 Apr 2022EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EDVA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

EDVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Endovia Health Sciences, Inc. returned −98.0% against +14.3% for the S&P 500, dividends included.

EDVA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26EDVAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EDVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Endovia Health Sciences, Inc. (EDVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
348.2×

Cheaper than 2% of US stocks

Price / book
−0.0×

Cheaper than 93% of US stocks

EV / EBITDA
−0.6×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−99.0%

Higher than 2% of US stocks

Gross margin
43.8%

Higher than 54% of US stocks

Operating margin
−165372.5%

Higher than 1% of US stocks

Net margin
23.1%

Higher than 84% of US stocks

Returns & dividend
Return on equity
164.9%

Higher than 98% of US stocks

Return on assets
−77.0%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Endovia Health Sciences, Inc. (EDVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Endovia Health Sciences, Inc. has a market value of $930K and an enterprise value of $8.6M.

  • Revenue in the twelve months to 30 June 2026: −$361K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$17.3M, a 4787.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$5.5M.

  • Shares outstanding: 4.0M.

  • Trailing P/E: −0.0×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Endovia Health Sciences, Inc. employs 1 people — −$361K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

EDVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBeverages - Wineries & Distilleries
CompanyMarket capTKN rank
EDVAEndovia Health Sciences, Inc.$929,815.003
EPSMEpsium Enterprise Ltd.$2.4M4
IBGInnovation Beverage Group Ltd.$3.7M2
AMSSAMASS Brands, Inc.$3.8M2
YHCLQR House, Inc.$3.9M7
WVVIWillamette Valley Vineyards, Inc.$9.5M40
GSUNGolden Sun Technology Group Ltd.*$1.9M43

* Nearest Consumer Defensive names by size — few beverages - wineries & distilleries companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Endovia Health Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EDVA news & analysis

Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

GlobeNewsWire · 5 Oct 2026positive

Endovia Health Sciences, in association with Lupvindol BioSciences, announced that the FDA's Center for Veterinary Medicine has determined their investigational CBD/THC oral solution CannEpil®, intended for controlling pain from bone cancer in dogs, qualifies as a "minor use" under the Minor Use and Minor Species program. This determination establishes eligibility for a conditional approval pathway.

Why it matters — This FDA designation creates a regulatory pathway for CannEpil® toward conditional approval, a notable milestone in Endovia's veterinary drug development pipeline.

Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways

GlobeNewsWire · 22 Sept 2026positive

Endovia Health Sciences, Inc. announced it has closed initial funding intended to accelerate development of its CannEpil® product. The financing comes as the FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines.

Why it matters — A EDVA watcher would care because the new funding supports progress on its CannEpil® pipeline, while growing federal attention on botanical drug pathways could create a more favorable regulatory environment for the company.

Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences

GlobeNewsWire · 20 Aug 2026neutral

Splash Beverage Group reported its financial results for the second quarter ended June 30, 2026, and provided an update on its ongoing strategic transformation toward Endovia Health Sciences.

Why it matters — SBEV watchers would care because this update confirms the company's continued shift toward its Endovia Health Sciences strategy alongside its quarterly results.

Splash Beverage Group to Rebrand as Endovia Health Sciences

GlobeNewsWire · 12 Aug 2026neutral

Splash Beverage Group announced it will change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026.

Why it matters — The rebranding signals a shift in corporate identity that SBEV shareholders will want to monitor for potential changes in business direction.

FAQ

Frequently asked questions about EDVA stock

Is EDVA stock a buy right now?

Of the 1 analysts covering Endovia Health Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Endovia Health Sciences, Inc. 3 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EDVA?

As at 23 Oct 2026, Endovia Health Sciences, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the EDVA stock forecast for 2030?

No analyst covering Endovia Health Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDVA are extrapolating price history, which says nothing about the business.

How has EDVA stock performed over the past year?

Endovia Health Sciences, Inc. returned -98.0% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Endovia Health Sciences, Inc. do?

Endovia Health Sciences, Inc. is a health sciences company focused on cannabinoid-based pharmaceutical, veterinary, and consumer wellness products.

What is the latest news on EDVA?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway". Endovia Health Sciences, in association with Lupvindol BioSciences, announced that the FDA's Center for Veterinary Medicine has determined their investigational CBD/THC oral solution CannEpil®, intended for controlling pain from bone cancer in dogs, qualifies as a "minor use" under the Minor Use and Minor Species program. This determination establishes eligibility for a conditional approval pathway.

Company

About Endovia Health Sciences, Inc.

Endovia Health Sciences, Inc. is a health sciences company focused on cannabinoid-based pharmaceutical, veterinary, and consumer wellness products. The company develops and commercializes differentiated health technologies across regulated human and animal health markets, with current emphasis on commercial pharmaceutical assets and FDA-regulated therapeutics. Its portfolio includes cannabinoid-based programs such as CannEpil®, which is being advanced for veterinary applications, alongside wellness-oriented offerings that extend its reach into consumer-facing health categories. Endovia Health Sciences operates as a diversified platform that combines product development, regulatory work, and market commercialization across multiple segments of the cannabinoid industry. The company serves markets that include pharmaceuticals, companion-animal health, and wellness products, positioning it as a specialized participant in emerging cannabinoid healthcare applications.

CEO Mr. Robert Nistico · 1 employees · United States · https://splashbeveragegroup.com